Today: 23 January 2026
Subscribe
Browse Category

TSX:2330.TW News 17 January 2026 - 19 January 2026

TSMC stock price: report flags four new Taiwan assembly plants as traders brace for Monday open

TSMC stock price: report flags four new Taiwan assembly plants as traders brace for Monday open

Taipei, January 19, 2026, 07:13 (GMT+8) — Premarket. Taiwan Semiconductor Manufacturing Co’s shares were in focus before trade in Taipei on Monday after Taiwan’s state-run Central News Agency reported the chipmaker stayed tight-lipped on a media report that it plans four new advanced integrated circuit (IC) assembly plants in Taiwan. (Focus Taiwan – CNA English News) The timing matters. Assembly…
19 January 2026
····
TSMC stock price jumps in Taiwan — what to watch before markets reopen

TSMC stock price jumps in Taiwan — what to watch before markets reopen

Taipei, Jan 17, 2026, 23:01 (TST) — Market closed. Taiwan Semiconductor Manufacturing Co (2330.TW) saw its shares climb 2.96% on Friday, closing at NT$1,740.00. On the other side of the globe, its American depositary receipts (ADRs)—which represent foreign shares in the U.S.—finished up 0.22%, at $342.40. (MarketWatch) With markets closed for the weekend, all eyes are on how the new…
17 January 2026
····

Stock Market Today

  • Genetic Engineering Tool Market Set to Reach $28.57 Billion by 2031 Driven by CRISPR Advances
    January 23, 2026, 6:51 AM EST. The Global Genetic Engineering Tool Market is forecast to grow at a 4.38% CAGR, expanding from $22.09 billion in 2025 to $28.57 billion by 2031. Key growth drivers include rapid technological progress in genome editing platforms like CRISPR-Cas9, which is transitioning from lab research to clinically approved therapies. Notably, the FDA's approval of CASGEVY underscores the commercial viability of gene-edited treatments. Increased funding in biotech and genomics fuels demand for advanced tools and instrumentation. However, stringent regulatory frameworks and ethical concerns over off-target effects delay clinical advances, hindering the shift to large-scale commercial tool procurement. Despite robust investment and nine new product approvals reported in 2024, regulatory hurdles remain a critical challenge for market expansion.
Go toTop